Therefore, lorlatinib resulted in a statistically significant clinical improvement in PFS vs. crizotinib and it should be considered a new first-line treatment option for patients with ALK-positive NSCLC [42,43]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.